Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30396496 | 0.85 | USP30 (0.55) | DGAT1HRH3USP30ALDH1A1KDM4E | |
| SCHEMBL17148720 | 0.85 | USP30 (0.55) | DGAT1HRH3USP30ALDH1A1KDM4E | |
| SCHEMBL30434278 | 0.84 | LTA4H (0.39) | DGAT1HRH3USP30KDM4E | |
| SCHEMBL15647594 | 0.84 | LTA4H (0.39) | DGAT1HRH3USP30KDM4E | |
| SCHEMBL21550453 | 0.84 | HRH3 (0.43) | DGAT1HRH3USP30 | |
| SCHEMBL22561593 | 0.82 | DGAT1 (0.38) | DGAT1HRH3USP30ALDH1A1ROCK1 | |
| SCHEMBL143358 | 0.82 | HRH3 (0.45) | DGAT1HRH3 | |
| SCHEMBL3416907 | 0.82 | HRH3 (0.47) | HRH3ALDH1A1 | |
| SCHEMBL15648977 | 0.81 | DGAT1 (0.40) | DGAT1USP30ALDH1A1 | |
| SCHEMBL30889384 | 0.81 | DGAT1 (0.40) | DGAT1USP30ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2024-05-23 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2021-03-04 | — | — | US | disclosed |
| EP-3725314-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-2906537-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10092572-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | DGAT1 3770/4885HRH3 1485/4885USP30 2972/4885 |
| US-10092572-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | DGAT1 3770/4885HRH3 1485/4885USP30 2972/4885 |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | DGAT1 3770/4885HRH3 1485/4885USP30 2972/4885 |
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | DGAT1 3770/4885HRH3 1485/4885USP30 2972/4885 |
| US-11642348-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | DGAT1 3770/4885HRH3 1485/4885USP30 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.